RxDoctor Payments Data

Shirley Govender

Psychiatric/Mental Health · Fort Myers, FLNPI 1225095649

Payments from drug & device makers

$1,216in general payments, 2019–2025

Across 18 payments — averaging $67.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$315
  • Teva Pharmaceuticals USA, Inc.$236
  • Axsome Therapeutics, Inc.$222
  • Neurocrine Biosciences, Inc.$125
  • Otsuka America Pharmaceutical, Inc.$125
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$123
  • plus $70 from 2 others

What the payments were for

  • Food & beverage$1,216100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,216 in reported general payments places this provider in the 60th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$3,017
Medicare patients
21
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl62$88,260
LybalviOlanzapine/Samidorphan Malate13$20,608
Aripiprazole68$12,934
Lurasidone Hcl11$3,292
Bupropion XlBupropion Hcl133$2,147
Venlafaxine Hcl ErVenlafaxine Hcl75$2,088
Buspirone Hcl150$1,577
Duloxetine Hcl136$1,570
Gabapentin107$1,398
Olanzapine60$1,275
Hydroxyzine Pamoate95$1,252
Quetiapine Fumarate71$1,090
Trazodone Hcl141$977
Ziprasidone Hcl11$927
Lamotrigine71$704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$315$88,26062 claims
Alkermes, Inc.Lybalvi$45$20,60813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →